儿童高级别软组织肉瘤的多参数评估:解剖与功能MRI序列的回顾性研究
回顾性纳入27例≤18岁经组织学确诊的软组织肉瘤患儿,比较治疗前后MRI解剖与功能序列特征并分析其与临床结局的相关性。治疗后肿瘤体积缩小(p=0.002)、ADC最小值与平均值升高,但体积变化与进展无关;ADC变化与疾病进展相关,提示ADC可能是潜在的临床结局生物标志物。
要点
- 治疗前肿瘤体积较大与基线转移(p=0.004)及进展(p=0.002)相关。
- ADC最小值与平均值的读者间一致性极好(ICC分别为0.991与0.978)。
- 进展组治疗前后ADC最小值与平均值差值较小(p=0.019与p=0.032)。
核心结论
- 儿童高级别软组织肉瘤治疗前体积是重要预后因素,治疗后体积缩小但与进展无关;治疗前后ADC值变化与疾病进展相关,提示ADC可能是临床结局的潜在有用生物标志物。
研究设计与样本
- 回顾性队列研究,连续纳入27例≤18岁经组织学确诊的软组织肉瘤患儿,均行含解剖与功能序列的MRI,部分有治疗后MRI,由两名读者记录特征。
关键影像表现/征象
- 治疗前测量肿瘤大小、ADC最小值(均值507×10-6mm2/s)与ADC平均值(均值690×10-6mm2/s)。
- 治疗后(10例)肿瘤大小减小(p=0.002),ADC最小值(均值1116×10-6mm2/s)与ADC平均值(均值1344×10-6mm2/s)升高。
诊断标准与关键数值
- ADC最小值读者间一致性ICC=0.991,ADC平均值ICC=0.978。
- 基线有转移者治疗前体积更大(p=0.004),进展者治疗前体积更大(p=0.002)。
- 基线ADC与进展无关,但进展组治疗前后ADC最小值差值较小(p=0.019)、ADC平均值差值较小(p=0.032)。
临床应用与阅片要点
- 治疗前肿瘤体积可用于提示基线转移与进展风险。
- 治疗前后ADC值变化与疾病进展相关,提示ADC可作为临床结局的潜在生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate multiparametric MRI features of pediatric soft-tissue sarcomas, comparing pre-treatment and post-treatment features, and assessing correlation with clinical outcomes.
MATERIALS AND METHODS: Retrospective cohort study, including pediatric patients (≤ 18 years) with histologically-confirmed soft-tissue sarcomas who underwent MRI with anatomic and functional sequences in consecutive series. Post-treatment MRI was available for a subset, and features were recorded by two readers. Pre-treatment and post-treatment features were compared using Wilcoxon signed-rank test with Hodges-Lehmann estimator. Inter-reader agreement was assessed with intraclass correlation coefficient, and Mann-Whitney and Cox regression tests were used to correlate the features with clinical outcome.
RESULTS: There were 27 patients. Pre-treatment we measured tumor size, ADCminimum (mean: 507 × 10-6mm2/s) and ADCaverage (mean: 690 × 10-6mm2/s). Post-treatment (10 patients) included a reduction in tumor size (p = 0.002) and higher ADCminimum (mean: 1116 × 10-6mm2/s) and ADCaverage (mean: 1344 × 10-6mm2/s) values. Pre-treatment size was larger in patients with metastasis at baseline (p = 0.004) and progression (p = 0.002), but size change after treatment did not correlate with progression. Baseline ADC did not correlate with progression, but the group with progression showed less difference between pre- and post-treatment ADCminimum (p = 0.019) and ADCaverage (p = 0.032). There was excellent agreement between the readers measuring ADCminimum (ICC = 0.991) and ADCaverage (ICC = 0.978).
CONCLUSION: For high-grade pediatric soft-tissue sarcomas, the pre-treatment size is an important prognostic factor, and a reduction in tumor size was observed after treatment, but did not correlate with progression. However, changes to ADC values between pre-treatment and post-treatment MRI correlated with disease progression, suggesting that ADC is a potentially useful biomarker of clinical outcome.
引用
- de Tarso Kawakami Perez P, Fayad LM, Rosa Pinto MB, et al. Multiparametric assessment of high-grade pediatric soft-tissue sarcomas with anatomic and functional MRI sequences: a retrospective study. Skeletal Radiol. 2025. PMID: 40921879. doi:10.1007/s00256-025-05025-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。